Marshall Wace LLP Acquires New Position in Replimune Group, Inc. (NASDAQ:REPL)

Marshall Wace LLP bought a new stake in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 896,184 shares of the company's stock, valued at approximately $10,853,000. Marshall Wace LLP owned approximately 1.31% of Replimune Group as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Sterling Capital Management LLC increased its holdings in shares of Replimune Group by 364.5% in the fourth quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock worth $26,000 after purchasing an additional 1,655 shares during the period. Aster Capital Management DIFC Ltd raised its stake in Replimune Group by 8,798.9% in the fourth quarter. Aster Capital Management DIFC Ltd now owns 8,276 shares of the company's stock valued at $100,000 after purchasing an additional 8,183 shares in the last quarter. XTX Topco Ltd bought a new stake in Replimune Group during the fourth quarter valued at approximately $137,000. Sei Investments Co. bought a new position in shares of Replimune Group in the 4th quarter worth $148,000. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Replimune Group in the 4th quarter worth $150,000. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Price Performance

Replimune Group stock traded down $0.01 during mid-day trading on Friday, hitting $9.05. The stock had a trading volume of 362,638 shares, compared to its average volume of 867,680. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The firm has a market capitalization of $696.99 million, a P/E ratio of -2.95 and a beta of 1.26. The firm's 50 day moving average is $10.24 and its 200 day moving average is $11.66.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09). On average, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. BMO Capital Markets increased their target price on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research note on Wednesday, January 22nd. HC Wainwright increased their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Replimune Group currently has an average rating of "Buy" and an average price target of $19.43.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.